Catalyst Wire Dossier Catalyst Wire Dossier

INGAP-Peptide

INGAP peptide · Exsulin Corporation
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for INGAP-Peptide, covering 2014-02-12 to 2017-05-30. Get the full timeline:

Most recent: Clinical Trial Update: Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis [Phase 2]

See pricing